KING OF PRUSSIA, Pa. -- (BUSINESS WIRE) -- Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the appointment of John M. Limongelli, Esq., to the newly created position of Senior Vice President, General Counsel & Corporate Secretary, effective immediately.
“John’s broad legal knowledge and deep industry experience will be invaluable as we continue to develop our product candidates and grow the company,” said Maxine Gowen, Ph.D., chief executive officer.
“I am excited to join the dedicated executive team at Trevena at this important time in the Company’s development,” stated Mr. Limongelli. “I look forward to supporting Trevena in its mission to unlock the potential of its proprietary biased ligand platform, which has the potential to address significant unmet medical needs.”
Mr. Limongelli, 44, brings over 15 years of strategic and legal experience representing public life sciences and healthcare companies. Since 2013, he was Vice President, Associate Chief Counsel and Corporate Secretary at Cigna Corporation. From 2008 to 2011, he served as Senior Vice President, General Counsel and Secretary at Adolor Corporation, a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain and pain management products. Prior to Adolor, Mr. Limongelli held roles of increasing responsibility with Cephalon, Inc., most recently serving as Vice President and Associate General Counsel. Mr. Limongelli began his legal career in private practice with Morgan, Lewis & Bockius, LLP, in Philadelphia; he also later served as a partner with a local Philadelphia-area firm after the sale of Adolor to Cubist Pharmaceuticals. Mr. Limongelli obtained both his Juris Doctor and Masters in Business Administration with honors from Temple University.
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced three differentiated biased ligand product candidates into the clinic – TRV027 to treat acute heart failure, TRV130 to treat moderate to severe acute pain intravenously, and TRV734 to treat moderate to severe acute and chronic pain orally. Trevena also plans to advance additional product candidates in its portfolio, including a preclinical program focused on central nervous system indications.